Treatment of low-risk gestational trophoblastic neoplasia
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 74, 67-80
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasiaBritish Journal of Cancer, 2012
- Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort studyThe Lancet, 2012
- Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2011
- The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l−1British Journal of Cancer, 2010
- Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasiasAnnals of Oncology, 2010
- Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic DiseaseJournal of Clinical Oncology, 2006
- Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low‐risk gestational trophoblastic neoplasiaAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2005
- Is Lack of Response to Single-Agent Chemotherapy in Gestational Trophoblastic Disease Associated with Dose Scheduling or Chemotherapy Resistance?Gynecologic Oncology, 2002
- Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumorsAmerican Journal of Obstetrics and Gynecology, 1995
- 5-Day Methotrexate for Women with Metastatic Gestational Trophoblastic DiseaseGynecologic Oncology, 1994